This clinical trial consists of two parts. The first part is a safety evaluation phase, and the second part is the maintenance treatment phase.

Before entering the maintenance phase, you will receive initial treatment for your cervical cancer. The type of initial treatment will be determined based on the treatment group assigned to you.

The initial treatment may include combinations of chemotherapy (medications that kill cancer cells) and targeted therapy (medications that work against specific cancer characteristics).

After completing the initial treatment phase, you will be randomly assigned to one of several treatment groups for maintenance therapy. Random assignment means that neither you nor your doctor will choose which group you are in.

The possible treatment groups include: sacituzumab tirumotecan (also called MK-2870) combined with pembrolizumab, with or without bevacizumab, or standard care treatment.

Standard care treatment may include combinations of medications such as paclitaxel, carboplatin, cisplatin, pembrolizumab, and bevacizumab.

All medications in this trial are given through intravenous infusion, which means they are delivered directly into a vein over a period of time.

The treatment will be given in cycles. Each cycle typically lasts a specific number of weeks, and the medications are administered on certain days within each cycle.

The exact dosage, frequency, and duration of each medication will depend on the treatment group assigned to you and will be determined by the study protocol.

You will continue receiving maintenance treatment for as long as the treatment is working and you are not experiencing unacceptable side effects.

Throughout the trial, you will have regular visits to the study site for monitoring and assessment.

During these visits, your health status will be evaluated, and any side effects or adverse events will be recorded.

Medical examinations and tests will be performed to assess how well the treatment is working and to monitor your overall health.

Your quality of life will be assessed using questionnaires that ask about your physical functioning, daily activities, and overall well-being.

Periodic imaging scans will be performed to evaluate the status of your cancer and determine if the disease is progressing, staying stable, or improving.

These assessments will be conducted according to established criteria called Response Evaluation Criteria in Solid Tumors Version 1.1, which is a standardized way to measure changes in tumors.

The scans will be reviewed both by your treating doctor and by independent reviewers who are not involved in your direct care.

Your safety will be continuously monitored throughout the trial. Any side effects or health changes will be documented and assessed.

If you experience side effects that are unacceptable or if your cancer progresses despite treatment, adjustments to your treatment may be made, or treatment may be discontinued.

Blood tests and other laboratory assessments will be performed regularly to monitor how your body is responding to the medications.

Treatment will continue until your cancer progresses, you experience unacceptable side effects, you decide to withdraw from the study, or your doctor determines it is no longer beneficial to continue.

When you stop receiving study treatment, a final assessment will be conducted to evaluate your overall health status.

After you stop receiving treatment, you will enter a follow-up period during which your health will continue to be monitored.

Follow-up visits or contacts may occur at specified intervals to assess your long-term health outcomes and survival.

The trial is expected to continue until 2033, which includes both the treatment and follow-up phases for all participants.